Zielgerichtete Erstdiagnostik bei Typ-1-Diabetes

Abstract

The incidence of type 1 and type 2 diabetes mellitus has been increasing simultaneously. Formerly, these two patients’ populations could be differentiated easily, but now, due to the overlapping of both groups, specified diagnostics are necessary. In order to substantiate a suspicion on diabetes, quantifying venous plasma glucose is the gold standard in diagnostics. As a precaution, determination of the HbA_1c and OGTT is recommended. It is not necessary to determinate antibodies in every new case of diabetes. In patients with a vague constellation of clinical picture diagnosis can be ensured by findings of uric ketones, BGA, IA-2- and GAD-antibodies and optionally C-peptide. Often T1DM is associated with PGAS. Therefore, once manifestation of diabetes is detected, screening autoimmune disorders is recommended directly and regularly every two years.

Typ-1-Diabetes mellitus (T1DM) nimmt weltweit zu und ist eine der häufigsten chronischen Erkrankungen im Kindesalter. Allerdings manifestiert sich ein T1DM nicht selten erst im Erwachsenenalter – dann wird die eindeutige klinische Abgrenzung zum Typ-2-Diabetes (T2DM) mitunter schwierig. Andere Diabetesformen und Autoimmunsyndrome müssen ebenfalls berücksichtigt werden. Dieser Beitrag stellt die Möglichkeiten einer zielführenden Diagnostik vor.

Schlüsselwörter

Typ-1-Diabetes - Erstmanifestation - Differenzialdiagnose - Diagnostik - Autoimmunität

Key words

type 1 diabetes mellitus - autoimmunity - diagnostic approach - differential diagnosis

• Literatur

• 1 World Health Organization. Global report on diabetes. 2016 http://www.who.int/diabetes/global-report/en/
• 2 Diabetes-Informationsdienst. Helmholtz Zentrum München. 2012 https://www.diabetesinformationsdienst-muenchen.de/erkrankungsformen/typ-1-diabetes/verbreitung/index.html
• 3 Patterson CC. Dahlquist GG. Gyurus E. et al. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033
• 4 Thomas N. Jones S. Weedon M. et al. Classifying diabetes by type 1 genetic risk shows autoimmune diabetes cases are evenly distributed above and below 30 years of age. UK: Institute of Biomedical and Clinical Science, University of Exeter Medical School; 2016 Abstract 264 http://www.easdvirtualmeeting.org/resources/classifying-diabetes-by-type-1-genetic-risk-shows-autoimmune-diabetes-cases-are-evenly-distributed-above-and-below-30-years-of-age
• 5 Jones KL. Role of obesity in complicating and confusing the diagnosis and treatment of diabetes in children. Pediatrics 2008; 121: 361-368
• 6 Zeitler P. Approach to the obese adolescent with new-onset diabetes. J Clin Endocrinol Metab 2010; 95: 5163-5170
• 7 Maahs DM. West NA. Lawrence JM. et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39: 481-497
• 8 Davis TM. Wright AD. Mehta ZM. et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005; 48: 695-702
• 9 Imperatore G. Boyle JP. Thompson TJ. et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012; 35: 2515-2520
• 10 Smyth S. Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006; 12: 75-80
• 11 Kerner WBJ. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie und Stoffwechsel 2012; 7: S84-S87
• 12 Zhang B. Kumar RB. Dai H. et al. A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes. Nat Med 2014; 20: 948-953
• 13 Wenzlau JM. Juhl K. Yu L. et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17040-17045
• 14 Neu A. Hofer SE. Karges B. et al. Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14,664 patients from 106 institutions. Diabetes Care 2009; 32: 1647-1648
• 15 Böhm BO. Dreyer M. Fritsche A. et al. S3-Leitlinie Therapie des Typ-1-Diabetes. Deutsche Diabetes Gesellschaft 2011 http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/DM_im_Kinder-_und_Jugendalter_20151206.pdf
• 16 Goldberg PA. Siegel MD. Sherwin RS. et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27: 461-467
• 17 Herold KC. Vignali DA. Cooke A. et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013; 13: 243-256
• 18 Cordell HJ. Todd JA. Multifactorial inheritance in type 1 diabetes. Trends Genet 1995; 11: 499-504
• 19 Morran MP. Vonberg A. Khadra A. et al. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med 2015; 42: 42-60
• 20 Lampasona V. Liberati D. Islet Autoantibodies. Curr Diab Rep 2016; 16: 53
• 21 McLaughlin KA. Richardson CC. Ravishankar A. et al. Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes. Diabetes 2016; 65: 1690-1698
• 22 Pihoker C. Gilliam LK. Hampe CS. et al. Autoantibodies in diabetes. Diabetes 2005; 54: S52-S61
• 23 Bluestone JA. Herold K. Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464: 1293-1300
• 24 Visperas A. Vignali DA. Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?. J Immunol 2016; 197: 3762-3770
• 25 Rodriguez-Calvo T. Sabouri S. Anquetil F. et al. The viral paradigm in type 1 diabetes: Who are the main suspects?. Autoimmun Rev 2016; 15: 964-969
• 26 Amiel SA. Pursey N. Higgins B. et al. Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance. BMJ 2015; 351: h4188
• 27 Fourlanos S. Dotta F. Greenbaum CJ. et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206-2212
• 28 Laugesen E. Ostergaard JA. Leslie RD. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med 2015; 32: 843-852
• 29 Brophy S. Davies H. Mannan S. et al. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011; CD006165
• 30 Stenstrom G. Gottsater A. Bakhtadze E. et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 2005; 54: S68-72
• 31 Hwangbo Y. Kim JT. Kim EK. et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic Acid decarboxylase antibody. Diabetes Metab J 2012; 36: 136-143
• 32 Buzzetti R. Di Pietro S. Giaccari A. et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007; 30: 932-938
• 33 Hawa MI. Kolb H. Schloot N. et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36: 908-913
• 34 Hawa MI. Buchan AP. Ola T. et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 2014; 37: 1643-1649
• 35 Pham MN. Hawa MI. Pfleger C. et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 2011; 54: 1630-1638
• 36 Pham MN. Hawa MI. Roden M. et al. Increased serum concentrations of adhesion molecules but not of chemokines in patients with Type 2 diabetes compared with patients with Type 1 diabetes and latent autoimmune diabetes in adult age: action LADA 5. Diabet Med 2012; 29: 470-478
• 37 Hansen MP. Matheis N. Kahaly GJ. Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes 2015; 6: 67-79
• 38 Kakleas K. Soldatou A. Karachaliou F. et al. Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). Autoimmun Rev 2015; 14: 781-797
• 39 Kim SH. Maturity-Onset Diabetes of the Young: What Do Clinicians Need to Know?. Diabetes Metab J 2015; 39: 468-477
• 40 Lowe LP. Metzger BE. Dyer AR. et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care 2012; 35: 574-580